国产帕屈磷酸钠对体外破骨细胞性骨吸收影响的研究  

Inhabitary effects of pamidronate made in China on osteoclastic bone resorption in vitro

作　　者：杨雁[1,2] 葛志东[1,2] 周爱武[1,2] 陈敏珠[1,2] 冷宗康[1,2] 张瑞君[1,2] 

机构地区：[1]安徽医科大学临床药理研究所 [2]南京药物研究所

出　　处：《中国药理学通报》1997年第2期141-143,共3页Chinese Pharmacological Bulletin

摘　　要：研究国产帕屈磷酸钠（ＡＰＤ）对破骨细胞性骨吸收的作用。采用破骨细胞的体外培养法和显微摄片、显微光密度仪扫描及计算机图像分析技术。结果表明：ＡＰＤ（５，５０与５００μｍｏｌ·Ｌ－１）使体外破骨细胞性骨吸收陷窝数日呈剂量依赖性减少，低浓度（５μｍｏｌ·Ｌ－１）ＡＰＤ的抑制作用明显高于同类进口药骨磷（ＧＬ２ＭＤＰ）；两药物可使吸收陷窝表面积明显降低。提示ＡＰＤ具有较强的直接抑制破骨细胞性骨吸收的作用，对骨质疏松症可能有一定的疗效。To study the effects of Pamidronate (APD) made in China and Bonefos (CL 2MDP, as positive control drug) on osteoclastic bone resorbing lacunae by means of culturing osteocasts on slices, the techniques of photomicrography, microdensitometric scan and computer image analysis. The results indicated that APD (5, 50 or 500 μmol·L -1 )caused dose dependent reduction in the numbers of osteoclastic bone resorbing lacunae. The suppression by the lowest effective, concentration of APD (5 μmol·L -1 ) was more remarkable than that of CL 2MDP. Both APD and CL 2MDP reduced the surface areas of osteoclastic bone resorbing lacunae. It is suggested that APD could directly suppress osteoclastic bone resorption and might be effective in osteoporosis.

关 键 词：帕屈磷酸钠 破骨细胞性 骨质吸收 骨质疏松 

分 类 号：R982[医药卫生—药品] R681[医药卫生—药学]